Compare Alphabet Inc Class A (GOOGL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Merck & Co., Inc. — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Alphabet Inc Class A is far larger — about 12.1× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Merck & Co., Inc. for 98 Days on average.
| GOOGL | MRK | |
|---|---|---|
Market Cap | $4.24T | $351.28B |
Volume | 23,392,850 | 7,969,665 |
Sector | Media | Health |
52-Week High | $402.62 | $156.43 |
52-Week Low | $236.59 | $82.49 |
Typical Hold Time | 85 Days | 98 Days |
Enterprise Value | $4.13T | $398.04B |
Dividend Yield | 0.25% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, with strong technical support at $346 and resistance at $352. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 32.8% profit margin. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $9.11 surpassing the $2.87 estimate. Analyst consensus remains overwhelmingly bullish with 87% buy ratings and a $431.83 price target, representing 24% upside potential.
Alphabet presents a compelling investment case driven by AI leadership, strong cash flow generation, and consistent earnings outperformance. Key risks include regulatory scrutiny, competitive pressures in search and cloud, and market volatility. The stock's current valuation at 17.48x P/E appears reasonable given growth prospects, while technical indicators suggest near-term consolidation within a defined trading range.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
